Publications by authors named "Chiara Premuda"
The 2023 European Respiratory Society Congress took place on a hybrid platform, with participants joining online and in-person in Milan, Italy. The congress welcomed over 20 000 attendees, bringing together exciting updates in respiratory science and medicine from around the world. In this article, early career members of Assembly 10 (Respiratory Infections) summarise a selection of sessions across a broad range of topics, including presentations on bronchiectasis, nontuberculous mycobacteria, tuberculosis, cystic fibrosis and coronavirus disease 2019.
View Article and Find Full Text PDFBackground: The effects of elexacaftor/tezacaftor/ivacaftor (ETI) on respiratory outcomes for people with cystic fibrosis (CF) were demonstrated by several clinical trials, mainly based on simple spirometry. However, gains in lung function may vary greatly between patients, and predictors of FEV change after treatment have yet to be defined.
Research Question: Which ventilatory parameters are involved in the heterogeneity of FEV change after 12-month ETI treatment in people with CF and advanced lung disease?
Study Design And Methods: This was a multicenter, observational, prospective cohort study at two major CF centers in Italy.
Article Synopsis
- Tracheal stenosis is a serious complication that can greatly affect a person's quality of life, and the COVID-19 pandemic has increased its occurrence due to more people needing long-term intubation or tracheostomy for severe cases.
- A study in Lombardy, Italy, observed 281 patients who had prolonged intubation or tracheostomy, finding that 8.5% developed tracheal stenosis after an average of 112 days.
- The research indicated that having a tracheostomy and consuming alcohol raised the likelihood of developing stenosis significantly, highlighting the need for monitoring patients post-intubation for at least 200 days.
Introduction: Over the last ten years an increasing prevalence and incidence of non-tuberculous mycobacteria (NTM) has been reported among patients with cystic fibrosis (CF) Viviani (J Cyst Fibros, 15(5):619-623, 2016). NTM pulmonary disease has been associated with negative clinical outcomes and often requires pharmacological treatment. Although specific guidelines help clinicians in the process of diagnosis and clinical management, the focus on the multidimensional assessment of concomitant problems is still scarce.
View Article and Find Full Text PDF